Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06556693 · ClinicalTrials.gov registry record · NA

Janus II Feasibility

A NA study of Sleep Apnea, sponsored by Zoll Medical Corporation.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
3
Study locations

NCT06556693: Recruiting NA study of Sleep Apnea, sponsored by Zoll Medical Corporation.

NCT06556693 is a NA study of Sleep Apnea that is actively recruiting participants, run by Zoll Medical Corporation. The registered enrollment target is 40 participants, below the 2,988-participant average among 36 other Sleep Apnea trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06556693, a NA study of Sleep Apnea, is actively recruiting participants, sponsored by Zoll Medical Corporation.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
3
Study locations

Study Summary

The objectives of this study are to evaluate the feasibility of the remedē® Dual Channel System at implant and overnight sleep studies and to assess chronic safety.

Primary Outcome

Serious adverse event related to implant procedure, device, or stimulation

Conditions Studied

Interventions

  • DEVICE Dual Channel Stimulation

Study Locations (3)

Arizona

  • The Insomnia and Sleep Institute of Arizona LLC - Scottsdale

Michigan

  • The University of Michigan Health-West - Wyoming

Ohio

  • The Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-08-12
Est. Completion 2034-12
Phase NA
Zoll Medical Corporation

24 total trials

What NCT06556693 shows while recruiting

NCT06556693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 2,988-participant average among 36 other Sleep Apnea trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Sleep Apnea appearing as the primary indexed condition, and to 1 intervention - of which Dual Channel Stimulation is the first listed.

NCT06556693 reports a single indexed study location in Arizona, Michigan, Ohio.

Frequently Asked Questions

What is clinical trial NCT06556693 about?

NCT06556693 is a clinical study titled "Janus II Feasibility". The objectives of this study are to evaluate the feasibility of the remedē® Dual Channel System at implant and overnight sleep studies and to assess chronic safety.

What is the current status of trial NCT06556693?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-08-12. Estimated completion is 2034-12.

What conditions does trial NCT06556693 study?

This clinical trial studies the following conditions: Sleep Apnea.

What interventions are being tested in trial NCT06556693?

The interventions under investigation include: Dual Channel Stimulation (DEVICE).

Who is sponsoring clinical trial NCT06556693?

This trial is sponsored by Zoll Medical Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06556693 being conducted?

This trial has 3 study locations across Arizona, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep Apnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06556693's enrollment target sits among peer trials

40 27th of 36 higher than 8 of 36 other Sleep Apnea trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sleep Apnea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06556693, the US trial registry maintained by the National Library of Medicine. NCT06556693 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.